Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 20, 2018February 20, 2018

Injections in Mice Eliminated Local and Distant Tumors, Study Shows

News

Injecting two immuno-enhancing agents in very small amounts directly into a solid tumor eliminated not only the local, and all distant tumors (metastasis), a new mouse study shows. The effectiveness ... Read more

February 15, 2018

Researchers Publish Report to Help Clinicians Manage Patient Use of Cannabis Products

News

As the number of states legalizing cannabis as pain relief for cancers like lymphoma and other medicinal and recreational purposes increases, researchers published a report to help clinicians guide patient ... Read more

February 9, 2018February 9, 2018

Triple Combo Therapy Improves Outcomes for Certain Mantle Cell Lymphoma Patients

News

Combining Imbruvica (ibrutinib) with Revlimid (lenalidomide) and Rituxan (rituximab) may improve the poor outcomes of relapsed mantle cell lymphoma patients with certain genetic alterations, a Phase 2 trial suggests. But ... Read more

February 7, 2018February 7, 2018

90% of Mycosis Fungoides Patients Improved After MRG-106 Treatment, Study Shows

News

MRG-106, an RNA-based therapy, induced clinical improvements in 90 percent of patients with mycosis fungoides – a subtype of cutaneous T-cell lymphoma (CTCL) – in a Phase 1 clinical trial testing ... Read more

February 6, 2018February 6, 2018

Cellectar Enrolls First DLBCL Patient in Phase 2 Trial Testing CLR 131 in Refractory B-cell Cancers

News

Cellectar Biosciences has recruited the first patient with diffuse large B-cell lymphoma (DLBCL) into its Phase 2 clinical trial testing the company’s lead investigational phospholipid-drug conjugate, CLR 131. The trial includes ... Read more

January 25, 2018

9 in 10 Mantle Cell Lymphoma Patients Benefit from Calquence, AstraZeneca Reports

News

Calquence (acalabrutinib) eliminated tumors in 40 percent of mantle cell lymphoma patients who took part in a Phase 2 clinical trial, AstraZeneca and Acerta Pharma reported. An additional 41 percent in the ACE-LY-004 trial ... Read more

January 3, 2018

FDA to Review Adcetris, Chemo Combo as First-line Treatment for Advanced Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin’s lymphoma, according to Seattle Genetics. The supplemental Biologics License ... Read more

January 2, 2018

Verastem to Seek FDA Approval for Duvelisib to Treat SLL and CLL After Consistently Positive Trial Results

News

Verastem‘s duvelisib significantly delays disease progression or death in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Phase 3 trial results. The trial, called ... Read more

December 13, 2017

40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta

News

More than a year after receiving the CAR T-cell therapy Yescarta (axicabtagene ciloleucel), 42 percent of the patients in the ZUMA-1 trial are still responding to the treatment, Kite Pharma announced. The Phase ... Read more

December 11, 2017

Aptevo to Launch Phase 2 Trial of Therapy Candidate for Peripheral T-cell Lymphoma

News

Aptevo Therapeutics, a biotech company developing new therapies for blood and lymph cancers, will soon launch a Phase 2 clinical trial to evaluate its monospecific antibody candidate, otlertuzumab, in patients ... Read more